• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A method of inhibiting parasites in or on an animal, comprising administering to said animal a substantially non-vomiting l-arylpyrazole having a parasitic effect.
    公开号:KR20010108006A
    申请号:KR1020017007046
    申请日:1999-12-10
    公开日:2001-12-07
    发明作者:리베일이브스；후버스코트케빈；엠꼼브수잔마리；말라스카마이클제임스；초우데이비드；페레즈데레옹아달베르토
    申请人:추후제출；아벤티스 크롭사이언스 소시에떼아노님；
    IPC主号:
    专利说明:

    Control of arthropods in animals {CONTROL OF ARTHROPODS IN ANIMALS}
    [2] It is generally the goal of agronomists and veterinarians to have sufficient means to control pests, particularly arthropods, which invade or attack mammals, particularly livestock and / or poultry. Conventional methods of inhibiting such pests have used local and / or systemic pesticides in affected animals in vitro or in vivo. In general, effective treatments include oral administration of insect growth inhibitors such as lufenuron, or topical application of anti-gonist compounds such as ivermectin or avermectin, or insecticidal fipronil. It is advantageous to apply pesticides to animals in oral form to prevent possible contamination of humans or the surrounding environment.
    [3] It is an object of the present invention to provide new pesticides that can be used in livestock.
    [4] Another object of the present invention is to provide a safer pesticide for livestock.
    [5] It is a further object of the present invention to provide new pesticides for livestock which can be used in smaller amounts than existing pesticides.
    [6] This object fulfills all or part of the invention.
    [1] The present invention relates to methods of inhibiting parasites in animals, compositions containing compounds effective for such inhibition and novel compounds effective against parasites.
    [7] The present invention provides a method for inhibiting a parasite in or outside an animal, comprising orally administering to the animal a substantial non-vomiting amount of 1-arylpyrazole of Formula I and a veterinary acceptable salt thereof that has a parasitic effect. Provides:
    [8]
    [9] [Meal,
    [10] R 1 is cyano, acetyl, C (S) NH 2 , alkyl, haloalkyl, C (═NOH) NH 2 or C (= NNH 2 ) NH 2 ;
    [11] R 2 is S (O) nR 3 ; C 2 -C 3 alkenyl, C 2 -C 3 haloalkenyl, cycloalkyl, halocycloalkyl or C 2 -C 3 alkynyl;
    [12] R 3 is alkyl or haloalkyl;
    [13] R 4 is -N = C (R 5 ) -ZR 6 , -N = C (R 5 ) -N (R 7 ) -R 8 , or -N (R 9 ) -C (R 5 ) = NR 6 ;
    [14] R 5 is hydrogen; Alkyl; Or halogen, alkoxy, haloalkoxy or alkyl substituted with -S (O) mR 15 ;
    [15] R 6 and R 7 are each independently hydrogen, alkyl, C 3 -C 5 alkenyl or C 3 -C 5 alkynyl; or
    [16] One or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or alkyl substituted with -S (O) mR 15 ; Or alkyl substituted with phenyl or pyridyl, each optionally substituted with one or more groups selected from halogen, nitro and alkyl; or
    [17] R 6 and R 7 together with the nitrogen to which they are attached may form a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from oxygen, nitrogen or sulfur;
    [18] R 8 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, R 14 CO- or —S (O) tR 10 ;
    [19] R 9 , R 10 and R 14 are alkyl or haloalkyl;
    [20] R 11 and R 12 are independently selected from halogen, hydrogen, CN and NO 2 ;
    [21] R 13 is selected from halogen, haloalkyl, haloalkoxy, -S (O) qCF 3 , and -SF 5 ;
    [22] R 15 is alkyl or haloalkyl;
    [23] X is selected from nitrogen and CR 12 ;
    [24] Z is O, S (O) a; Or NR 7 ;
    [25] a, m, n and q are independently selected from 0, 1 and 2;
    [26] t is 0 or 2].
    [27] In another aspect, the present invention includes orally administering to an animal a substantially non-vomiting amount of 1-arylpyrazole of Formula (XX) and its veterinary acceptable salt, which has a parasitic effect. Provides a way to suppress parasites:
    [28]
    [29] [In the meal,
    [30] R 201 is cyano, C (O) alkyl, C (S) NH 2 , alkyl, C (═NOH) NH 2 or C (= NNH 2 ) NH 2 ;
    [31] R 202 is S (O) hR 203 , C 2 -C 3 alkenyl, C 2 -C 3 haloalkenyl, cycloalkyl, halocycloalkyl or C 2 -C 3 alkynyl;
    [32] R 203 is alkyl or haloalkyl;
    [33] R 204 is —N (R 205 ) C (O) CR 206 R 207 R 208 , -N (R 205 ) C (O) aryl, or —N (R 205 ) C (O) OR 207 ;
    [34] R 205 is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, cycloalkylalkyl, halocycloalkylalkyl, alkoxyalkyl, haloalkoxyalkyl, C 3 -C 5 alkenyl, C 3 -C 5 haloalkenyl, C 3 -C 5 alkynyl, C 3 -C 5 haloalkynyl;
    [35] R 206 is hydrogen, halogen, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl, formyloxy, alkylcarbonyloxy, haloalkylcarbonyloxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, Alkylsulfonyl, haloalkylsulfonyl, alkylamino, dialkylamino, haloalkylamino, di (haloalkyl) amino, cycloalkyloxy, halocycloalkyloxy, alkoxyalkoxy, haloalkoxyalkoxy, alkoxyalkoxyalkoxy, aryloxy, Or arylalkoxy;
    [36] R 207 and R 208 are independently hydrogen, alkyl, haloalkyl, cycloalkyl, or halocycloalkyl; Or R 207 and R 208 together with the carbon to which they are bound may form a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;
    [37] X 1 is selected from nitrogen and CR 212 ;
    [38] R 211 and R 212 are independently selected from halogen, hydrogen, CN and NO 2 ;
    [39] R 213 is selected from halogen, haloalkyl, haloalkoxy, -S (O) kCF 3 , and -SF 5 ;
    [40] h and k are independently selected from 0, 1 and 2].
    [41] The term "veterinarily acceptable salt" is known and means salts of anions that are permitted in the art for the formation of veterinary salts. As suitable acid addition salts formed by, for example, compounds of the formulas (I) and (XX), containing basic nitrogen atoms, for example amino groups, with inorganic acids such as hydrochlorides, sulfates, phosphates and nitrates Salts and salts with organic acids such as acetic acid.
    [42] Unless otherwise specified, alkyl and alkoxy groups are generally lower alkyl and alkoxy groups having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. Generally, haloalkyl, haloalkoxy and alkylamino groups have 1 to 4 carbon atoms. Haloalkyl and haloalkoxy groups may have one or more halogen atoms; Preferred groups of this kind include -CF 3 and -OCF 3 . Cycloalkyl groups generally have 3 to 6 carbon atoms, preferably 3 to 5 carbon atoms, and may be substituted with one or more halogen atoms. Alkenyl, haloalkenyl, alkynyl, and haloalkynyl groups generally have 3 to 5 carbon atoms. The term aryl generally means phenyl, pyridyl, furyl, and thiophenyl, each being one or more halogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, hydroxy, amino, alkylamino or dialkylamino Is substituted. In the compounds of formula (I), the term substituted alkyl is one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or alkyl substituted with -S (O) mR 15 ; Or alkyl substituted with phenyl or pyridyl, each optionally substituted with one or more groups selected from halogen, nitro and alkyl; Wherein R 15 is alkyl or haloalkyl and m is 0, 1 or 2; Preferably in the compounds of the formula (I), the alkyl group is generally substituted with 1 to 5 halogen atoms, preferably 1 to 3 halogen atoms. Chlorine and fluorine atoms are preferred.
    [43] Compounds of formula (I) wherein R 4 is -N = C (R 5 ) -ZR 6 , Z is NR 7 and R 6 represents a hydrogen atom, are tautomeric double bond isomeric forms -NH-C (R 5 ) = NR 7 may exist. Both forms are understood to be included in the present invention.
    [44] Radicals of the following examples are provided in the compound of formula XX:
    [45] An example of cycloalkyl is cyclopropylmethyl;
    [46] An example of cycloalkoxy is cyclopropyloxy;
    [47] Examples of alkoxyalkyl are CH 3 OCH 2 —;
    [48] Examples of alkoxyalkoxy are CH 3 OCH 2 O—;
    [49] Examples of alkoxyalkoxyalkoxy are CH 3 OCH 2 OCH 2 O—;
    [50] Examples of aryloxy are phenoxy radicals;
    [51] Examples of arylalkoxy radicals are benzyloxy or 2-phenylethoxy.
    [52] In general, in dialkylamino or di (haloalkyl) amino radicals, the alkyl and haloalkyl groups on nitrogen may be selected independently of one another.
    [53] It is also understood that enantiomeric and diastereomeric forms of the compounds of Formulas (I) and (XX) and salts thereof are included in the present invention. Compounds of formula (I) are generally prepared by known methods, for example as described in European patent application 511845, or by other methods according to the knowledge of those skilled in the chemical synthesis art.
    [54] The term non-emetic means a compound that generally does not cause nausea from the animal when a protective, prophylactic or cleaning dose is administered to the animal. The term emesis means vomiting. In general, the vomiting substance causes said vomiting less than 24 hours after administration, preferably less than 8 hours, more preferably less than 2 hours. In general, when the compounds of the present invention are administered to a group of animals, more than 70%, preferably more than 80%, most preferably more than 90% of the animals are free of vomiting.
    [55] Preferred classes of compounds of formula I for use in inhibiting parasites in animals are:
    [56] R 1 is cyano or alkyl;
    [57] R 2 is S (O) nR 3 ;
    [58] R 3 is alkyl or haloalkyl;
    [59] R 4 is -N = C (R 5 ) -ZR 6 ;
    [60] R 5 is hydrogen, alkyl or haloalkyl;
    [61] Z is O, S (O) a; Or NR 7 ;
    [62] R 6 and R 7 are independently selected from hydrogen and unsubstituted or substituted alkyl; or
    [63] R 6 and R 7 together with the nitrogen to which they are attached form a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from oxygen, nitrogen or sulfur; X is selected from nitrogen and CR 12 ;
    [64] R 11 and R 12 are independently selected from halogen, hydrogen, CN and NO 2 ;
    [65] R 13 is selected from halogen, haloalkyl, haloalkoxy, -S (O) qCF 3 , and -SF 5 ;
    [66] a, n and q are independently selected from 0, 1 and 2.
    [67] Preferably R 6 is at least one halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, sulfide, sulfoxide, sulfone, or at least one phenyl or pyridyl moiety selected from halo, nitro, and alkyl Alkyl substituted with phenyl or pyridyl moiety optionally substituted with groups.
    [68] Preferably the method of the invention has one or more of the following features:
    [69] R 1 is cyano;
    [70] R 4 is -N = C (R 5 ) -ZR 6 and Z is -NR 7 ;
    [71] X is CR 12 ; R 11 and R 12 represent a chlorine atom; R 13 is CF 3 , OCF 3 or -SF 5 ;
    [72] R 12 is —S (O) nCF 3 and n is 0, 1 or 2.
    [73] More preferred classes of compounds of formula I for use in inhibiting parasites in animals are:
    [74] R 1 is cyano or alkyl; R 4 is -N = C (R 5 ) -ZR 6 ; R 5 is hydrogen or C 1 -C 3 alkyl.
    [75] Compounds of formula I for use in inhibiting parasites in animals have one or more of the following characteristics:
    [76] R 1 is cyano or methyl;
    [77] R 3 is halomethyl (preferably CF 3 );
    [78] R 11 and R 12 independently represent a halogen atom;
    [79] X is CR 12 ;
    [80] R 13 is halo alkyl (preferably CF 3 ), halo alkoxy (preferably OCF 3 ), or —SF 5 ; or
    [81] n is 0, 1, or 2 (preferably 0 or 1).
    [82] A more preferred class of compounds of formula (I) for use in inhibiting parasites in animals has one or more of the following characteristics:
    [83] R 1 is cyano;
    [84] R 2 is S (O) nR 3 ;
    [85] R 3 is halomethyl;
    [86] R 4 is -N = C (R 5 ) -ZR 6 ;
    [87] Z is NR 7 ;
    [88] R 5 is hydrogen or alkyl;
    [89] R 6 and R 7 are each independently hydrogen, alkyl, alkenyl or alkynyl; Or one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S (O) mR 15 ; Or alkyl in which the ring is substituted with phenyl or pyridyl optionally substituted with one or more groups selected from halogen, nitro and alkyl;
    [90] X is selected from nitrogen and CR 12 ;
    [91] R 11 and R 12 each independently represent a halogen atom;
    [92] R 13 is selected from haloalkyl, haloalkoxy and -SF 5 ;
    [93] R 15 is alkyl or haloalkyl;
    [94] m and n are independently selected from 0, 1, and 2.
    [95] A more preferred class of compounds of formula I for use in suppressing parasites in animals is as follows:
    [96] R 1 is cyano;
    [97] R 2 is S (O) nCF 3 ;
    [98] R 4 is -N = C (R 5 ) -ZR 6 or -N = C (R 5 ) -N (R 7 ) -R 8 ;
    [99] Z is NR 7 ;
    [100] R 5 is hydrogen or alkyl;
    [101] R 6 and R 7 are each independently hydrogen, alkyl, alkenyl or alkynyl; Or alkyl substituted with one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S (O) mR 15 ; Or methyl substituted with phenyl or pyridyl optionally substituted with one or more groups selected from halogen, nitro and alkyl;
    [102] R 8 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino or —S (O) tR 10 ;
    [103] X is selected from nitrogen and CR 12 ;
    [104] R 10 and R 15 independently represent alkyl or haloalkyl;
    [105] R 11 and R 12 each represent a chlorine atom;
    [106] R 13 is CF 3 or -SF 5 ;
    [107] m and n are 0, 1 or 2; t is 0 or 2.
    [108] More preferred classes of compounds of formula I for use in inhibiting parasites in animals are:
    [109] R 1 is cyano;
    [110] R 2 is S (O) nCF 3 ;
    [111] R 4 is -N = C (R 5 ) -ZR 6 ;
    [112] Z is NR 7 ;
    [113] R 5 is hydrogen or methyl;
    [114] R 6 and R 7 are each independently hydrogen, alkyl, alkenyl or alkynyl; Or alkyl substituted with one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S (O) mR 15 ; Or alkyl in which the ring is substituted with phenyl or pyridyl optionally substituted with one or more groups selected from halogen, nitro and alkyl;
    [115] X is CR 12 ;
    [116] R 11 and R 12 each represent a chlorine atom;
    [117] R 13 is CF 3 or -SF 5 ;
    [118] R 15 is alkyl or haloalkyl;
    [119] m is 0, 1, or 2;
    [120] n is 0 or 1;
    [121] To be used to suppress parasites in animals
    [122] More preferred classes of compounds of formula I are the following:
    [123] R 1 is cyano;
    [124] R 2 is S (O) nCF 3 ;
    [125] R 4 is -N = C (R 5 ) -ZR 6 ;
    [126] Z is NR 7 ;
    [127] R 5 and R 7 each represent a hydrogen atom;
    [128] R 6 is alkyl or haloalkyl;
    [129] X is CR 12 ;
    [130] R 11 and R 12 each represent a chlorine atom;
    [131] R 13 is CF 3 or -SF 5 ;
    [132] n is zero.
    [133] Preferred compounds of formula XX according to the invention are the following:
    [134] Wherein R 201 is cyano;
    [135] R 202 is S (O) hR 203 ;
    [136] R 203 is alkyl or haloalkyl;
    [137] R 204 is —N (R 205 ) C (O) CR 206 R 207 R 208 ;
    [138] R 205 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl and halocycloalkylalkyl;
    [139] R 206 is alkoxy, haloalkoxy, or hydrogen;
    [140] R 207 and R 208 are independently hydrogen, alkyl, or haloalkyl; or
    [141] R 207 and R 208 together with the carbon to which they are bound may form a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;
    [142] X 1 is selected from nitrogen and CR 212 ;
    [143] R 211 and R 212 are independently selected from halogen, hydrogen, CN and NO 2 ;
    [144] R 213 is selected from halogen, haloalkyl, haloalkoxy, -S (O) kCF 3 , and -SF 5 ;
    [145] h and k are independently 0, 1, and 2.
    [146] A preferred group of compounds of formula (XX) are those in which the ring formed by R 207 and R 208 is interrupted by one or more heteroatoms, more preferably one oxygen atom.
    [147] The compounds of formula (I) of the invention preferably have one or more of the following features:
    [148] R 201 is cyano;
    [149] R 203 is halomethyl, preferably CF 3 ;
    [150] R 211 and R 212 are independently halogen;
    [151] X 1 is CR 212 ;
    [152] R 213 is haloalkyl, haloalkoxy or -SF 5 ; or
    [153] h is 0 or 1, or 2, preferably 0 or 1.
    [154] Preferred classes of compounds are those in which R 204 is N (R 205 ) C (O) CR 206 R 207 R 208 .
    [155] Another preferred class of compounds is that R 204 is N (R 205 ) C (O) aryl.
    [156] Another preferred class of compounds is that R 204 is N (R 205 ) C (O) OR 207 .
    [157] Preferably R 205 is C 1 -C 4 alkyl, more preferably C 1 -C 2 alkyl, most preferably methyl.
    [158] Preferably R 206 is alkoxy, most preferably methoxy, ethoxy or propoxy.
    [159] Preferably both R 207 and R 208 are hydrogen.
    [160] Among the compounds that can be used in the present invention, some are novel and therefore in another aspect of the present invention there is provided a compound of formula (II) or a veterinary acceptable salt thereof:
    [161]
    [162] [In the meal,
    [163] R 21 is cyano, alkyl, haloalkyl, acetyl, or -C (= S) NH 2, C (= NOH) NH 2 or C (= NNH 2) NH 2, and;
    [164] R 22 is S (O) mR 23 ;
    [165] R 23 is alkyl or haloalkyl;
    [166] R 24 is -N = C (R 25 ) N (R 26 ) (R 27 ) or -N = C (R 25 ) -N (R 27 ) -R 28 ;
    [167] R 25 is hydrogen or alkyl; Or alkyl substituted with one or more halogen, alkoxy, haloalkoxy or -S (O) mR 35 ;
    [168] R 26 and R 27 are each independently hydrogen, alkyl, alkenyl or alkynyl; Or alkyl substituted with one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S (O) mR 35 ; Or alkyl substituted with phenyl or pyridyl optionally substituted with one or more groups selected from halogen, nitro and alkyl; Wherein R 35 is alkyl or haloalkyl and m is 0, 1 or 2;
    [169] X is selected from nitrogen and CR 32 ;
    [170] R 28 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino or —S (O) tR 30 ;
    [171] R 30 is alkyl or haloalkyl;
    [172] R 31 and R 32 are independently selected from halogen, hydrogen, CN and NO 2 ;
    [173] R 33 is selected from halogen, haloalkyl, haloalkoxy, -S (O) rCF 3 , and -SF 5 ;
    [174] m and r are independently selected from 0, 1 and 2; t is 0 or 2;
    [175] Provided that R 21 is cyano; R 22 is SCF 2 CH 3 ; R 25 is hydrogen; X is CR 32 ; R 26 and R 27 are methyl; R 31 and R 32 are chlorine; Compounds wherein R 33 is trifluoromethyl are excluded.
    [176] Additional classes of novel compounds of formula II are:
    [177] R 21 is cyano or methyl;
    [178] R 22 is S (O) mR 23 ;
    [179] R 23 is haloalkyl;
    [180] R 24 is —N═C (R 25 ) N (R 26 ) (R 27 );
    [181] R 25 and R 27 are hydrogen or unsubstituted or substituted alkyl;
    [182] R 26 is haloalkyl;
    [183] X is selected from nitrogen and CR 32 ;
    [184] R 31 and R 32 are independently selected from halogen, hydrogen, CN and NO 2 ;
    [185] R 33 is selected from halogen, haloalkyl, haloalkoxy, -S (O) rCF 3 , or -SF 5 ;
    [186] m and r are independently selected from 0, 1 and 2;
    [187] Provided that R 21 is cyano; R 22 is -SCF 2 CH 3 ; R 25 is hydrogen; X is CR 32 ; R 26 and R 27 are methyl; R 31 and R 32 are chlorine; Compounds in which R 33 is trifluoromethyl are excluded.
    [188] Preferred classes of novel compounds of formula (II) are:
    [189] R 21 is cyano;
    [190] R 22 is S (O) mR 23 ;
    [191] R 23 is halomethyl;
    [192] R 24 is —N═C (R 25 ) N (R 26 ) (R 27 );
    [193] R 25 is hydrogen or alkyl;
    [194] R 26 and R 27 are each independently hydrogen, alkyl, alkenyl or alkynyl; Or alkyl substituted with one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S (O) mR 15 ; Or alkyl substituted with phenyl or pyridyl optionally substituted with one or more groups selected from halogen, nitro and alkyl; Wherein R 15 is alkyl or haloalkyl and m is 0, 1 or 2;
    [195] X is selected from nitrogen and CR 32 ;
    [196] R 31 and R 32 each represent a chlorine atom;
    [197] R 33 is selected from haloalkyl, haloalkoxy and -SF 5 ;
    [198] m is selected from 0, 1 and 2.
    [199] More preferred classes of novel compounds of formula II are:
    [200] R 21 is cyano;
    [201] R 22 is S (O) mCF 3 ;
    [202] R 24 is —N═C (R 25 ) N (R 26 ) (R 27 ); Or -N = C (R 25 ) -N (R 27 ) -R 28 ;
    [203] R 25 is hydrogen or methyl;
    [204] R 26 and R 27 are each independently hydrogen, alkyl, alkenyl or alkynyl; Or alkyl substituted with one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S (O) mR 15 ; Or methyl substituted with phenyl or pyridyl optionally substituted with one or more groups selected from halogen, nitro and alkyl; Wherein R 15 is alkyl or haloalkyl and m is 0, 1 or 2;
    [205] R 28 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino or —S (O) tR 30 ;
    [206] X is selected from nitrogen and CR 32 ;
    [207] R 30 is alkyl or haloalkyl;
    [208] R 31 and R 32 each represent a chlorine atom;
    [209] R 33 is CF 3 or -SF 5 ;
    [210] m is 0, 1 or 2; t is 0 or 2.
    [211] More preferred classes of novel compounds of formula II are:
    [212] R 21 is cyano;
    [213] R 22 is S (O) mCF 3 ;
    [214] R 24 is —N═C (R 25 ) N (R 26 ) (R 27 );
    [215] R 25 and R 27 each independently represent hydrogen or methyl;
    [216] R 26 is hydrogen, alkyl, alkenyl or alkynyl; Or alkyl substituted with one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S (O) mR 15 ; Or methyl substituted with phenyl or pyridyl optionally substituted with one or more groups selected from halogen, nitro and alkyl; R 15 is alkyl or haloalkyl and m is 0, 1 or 2;
    [217] X is selected from nitrogen and CR 32 ;
    [218] R 31 and R 32 each represent a chlorine atom;
    [219] R 33 is CF 3 or -SF 5 ;
    [220] m is 0, 1 or 2.
    [221] Particularly preferred classes of novel compounds of formula (II) are the following:
    [222] R 21 is cyano;
    [223] R 22 is S (O) mCF 3 ;
    [224] R 24 is —N═C (R 25 ) N (R 26 ) (R 27 );
    [225] R 25 and R 27 each represent a hydrogen atom;
    [226] R 26 is alkyl or (preferably) haloalkyl;
    [227] X is CR 32 ;
    [228] R 31 and R 32 each represent a chlorine atom;
    [229] R 33 is CF 3 or -SF 5 ;
    [230] m is zero.
    [231] In another aspect of the invention, there is provided a compound of formula XX or salts thereof, wherein the compound is 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5- (N -Ethoxycarbonyl-N-methyl) amino-4-trifluoromethylthiopyrazole.
    [232] More preferably, the following compounds of the formulas I and XX listed in Tables 1 to 13 are preferred according to the invention. Compound numbers are for identification purposes only. The following symbols are defined as follows: Me means methyl; Et means ethyl; n-Pr means n-propyl; i-Pr means isopropyl; n-Bu means n-butyl, n-Pent means n-pentyl; Cy means cyclopropyl.
    [233]
    [234]
    [235] Note: Compound number 232 is an acetate salt and compound number 233 is a citrate salt.
    [236]
    [237] The following compounds of the formula XX listed in Tables 4 to 12 are preferred according to the invention.
    [238]
    [239] [Continued Table 4]
    [240]
    [241]
    [242] Table 5 Continued
    [243]
    [244] Compound 3-3 was separated into its enantiomers R3-3 and S3-3.
    [245]
    [246] Table 6 continued
    [247]
    [248]
    [249] Compound 1-7 was also separated into its enantiomers (R) 1-7 and (S) 1-7.
    [250]
    [251] Compound 1-9 is separated into (R, R) 1-9, (S, R) 1-9, (S, S) 1-9, (R, S) 1-9, which are diastereomers thereof. The first name of the absolute structure is referred to as sulfoxide moiety, and the second as chiral carbon.
    [252]
    [253] Compound 1-11 was also separated into diastereomers (R) 1-11 and (S) 1-11.
    [254]
    [255]
    [256] Table 11 Continued
    [257]
    [258]
    [259]
    [260] Table 13 Continued
    [261]
    [262] The present invention also relates to a composition containing a substantially non-vomiting amount of a compound of formula (I) or a salt thereof, or a compound of formula (XX) or a salt thereof and an acceptable carrier which has a parasitic effect. Acceptable carriers for the use of the compounds are generally known to those skilled in the art for pest control in animals, especially livestock, most preferably dogs or cats.
    [263] Compositions that can be used in the present invention may generally contain from about 0.001 to 95% of a compound of formula (I) or a salt thereof or a compound of formula (XX) or a salt thereof. The remainder of the composition up to 100% generally contains various additives as well as carriers. In this specification and the appended claims,% is weight percent.
    [264] Diluted liquid formulations generally contain from about 0.001 to about 3%, preferably from about 0.1 to about 0.5% of a compound of formula I or a salt thereof or a compound of formula XX or a salt thereof.
    [265] Solid dosage forms generally contain from about 0.1 to about 8%, preferably from about 0.5 to about 1.5% of a compound of formula (I) or a salt thereof, or a compound of formula (XX) or a salt thereof.
    [266] Compositions for oral administration include, for example, tablets, pills, capsules, gels, potions, medicated feeds, medicinal beverages, medicinal feed aids, sustained release or other sustained-release devices intended to be retained in the gastrointestinal tract. And one or more compounds of Formula (I) or salts thereof, or compounds of Formula (XX) or salts thereof, associated with a veterinary acceptable carrier or coating. Among these, the active ingredient may be incorporated into a microcapsule or coated with an acid labile or alkali labile or other pharmaceutically acceptable enteric coating. Feed premixes or concentrates comprising the compounds of the invention for use in the preparation of medicinal feeds, beverages or other substances ingested by animals may also be used. In a very preferred embodiment, the composition is administered after eating, preferably immediately after eating and up to 2 hours after eating.
    [267] In a very preferred embodiment, when the animal is easily chewable and provided by hand to the animal, there is generally provided a product that does not tolerate human contamination.
    [268] The compound of formula (I) or a salt thereof, or a compound of formula (XX) or a salt thereof may be administered before, during or after meals. Compounds of formula (I) or salts thereof, or compounds of formula (XX) or salts thereof may be mixed with the carrier and / or food.
    [269] According to the invention, the compound of formula (I) or a salt thereof, or a compound of formula (XX) or a salt thereof is generally present in the animal at 0.1 to 500 mg / kg, preferably 1 to 100 mg per kilogram of body weight of the animal. / kg, more preferably 1 to 50 mg / kg, even more preferably 2 to 25 mg / kg, most preferably 3 to 15 mg / kg of a compound of formula I or a salt thereof or a compound of formula XX or It is administered orally in a single dose of its salt.
    [270] According to the invention, the treatment frequency of the animal, preferably the livestock, treated with the compound of formula I or a salt thereof, or the compound of formula XX or a salt thereof is generally from about once a week to about once a year, preferably Is about once every two weeks to about once every six months, more preferably once every two weeks to once every three months, and most preferably once every two weeks to once every six weeks.
    [271] Animals to be treated in general are livestock, preferably companion livestock. More preferably the animals to be treated are dogs and / or cats.
    [272] The compounds of the present invention may be most advantageously administered in conjunction with other parasitic effect substances, such as parasitic and / or parasitic parasitic agents, and / or endecto parasitic agents. For example, the compound may be selected from macrocyclic lactones such as avermectin or milbamycin, for example ivermectin; Pyratel (generally administered as pyrantel pamoate) or insect growth regulators such as lufenuron or metoprene.
    [273] As used herein and in the claims, the term "parasite" refers to endoparasites and ectoparasites of warm-blooded animals, and in particular to external parasites. Preferably, fleas and / or mites are suppressed by the method of the present invention.
    [274] Description of specific parasites of various host animals that can be inhibited by the method of the present invention includes the following arthropods:
    [275] Mite : mesostigma spp., Eg, chicken mites, Dermanyssus gallinae ; Itch or scab mite Sarcoptidae spp. For example, Sarcoptes scabiei ; Psorotidae spp., Including Chorioptes bovis and Psoroptes ovis . Such as mange mites; Chiggers, for example Trombiculida spp. For example, North American larvae , Trombicula alfreddugesi ;
    [276] Mites: for example, the Argasidae spp. For example, Argas spp. Ornithine and Todo Los spp (Ornithodoros). Soft tick, including; Ixodidae spp., For example, Rhipisephalus sanguineus , and Boophilus spp. Hard tick, including;
    [277] Lice : sucking teeth , for example, Menopon spp. And Bovicola spp. ; Biting teeth, for example, Haematopinus spp., Linognathus spp. And Solenopotes spp .;
    [278] Fleas: for example, Ctenocephalides spp. Such as dog fleas ( Ctenocephalides canis ) and cat fleas ( Ctenocephalides felis ); Xenopsylla spp. Such as Oriental rat fleas [ Xenopsylla cheopis ]; And fullex spp. Such as human fleas [ Pulex irritans ];
    [279] Sedum: For example, bedbugs or common bed bugs ( Cimex lectularius ); Triatominae spp. Comprising triatomid worms known as kissing worms; For example, Rhodnius prolixus and Triatoma spp .;
    [280] Vampire adult flies: (eg, Haematobia irritans on horns, Tabanus spp. On lights out, Chimney [ Stomoxys calcitrans ], horns on Simulium spp., Chrysops spp. On leaves, Melophagus ovinus ] Tsetse fly [ Glossina spp.], Mosquito [ Culex spp., Anopheles spp., And Aedes spp.]); And
    [281] Parasitic fly maggots: (eg, horsefly larvae [ Oestrus ovis and Cuterebra spp.], Black fly [ Phaenicia spp.], Gold fly [ Cochliomvia hominivorax ], bovine grub [ Hypoderma spp.], Fleece beetle.
    [282] The invention also preferably relates to the use of a compound of formula (I) or a salt thereof, or a compound of formula (XX) or a salt thereof, as described above, as a therapeutic agent for an animal, more preferably a livestock.
    [283] The veterinary composition can be sterile or non-sterile. This may be a liquid (eg aqueous) or solid (eg dry) composition, in particular a freeze-dried composition, in which an orally effective solution may be prepared by the addition of water or another liquid.
    [284] The invention also relates to the use of a compound of formula (I) or a salt thereof as defined above, or a compound of formula (XX) or a salt thereof, for the preparation of a veterinary composition for the inhibition of parasites in or on an animal.
    [285] The present invention also relates to a method for cleaning a healthy animal comprising applying to the animal a compound of formula (I) or a salt thereof, or a compound of formula (XX) or a salt thereof as defined above.
    [286] The method of cleaning an animal is not a treatment by the animal body itself, for the following reasons:
    [287] (a) the animal is healthy and does not require substantial treatment to correct the lack of health;
    [288] (b) the cleaning of the animal is not intended to be performed by veterinary medical personnel, but is by a person interested in cleaning the animal;
    [289] (c) The purpose of the cleaning is to avoid living conditions that are unpleasant to humans and that humans are not infected by arthropods carried by animals.
    [290] "Carrier" means an organic or inorganic material that can be natural or synthetic, is associated with a compound, and facilitates its application to an animal. Such carriers are therefore generally inert and should be arthropodally acceptable. The carrier may be a solid (eg clay, silicate, silica, resin, wax) or a liquid (eg water, alcohol, ketone, oil solvent, polar aprotic solvent). An example of an oil solvent is corn oil. An example of a polar aprotic solvent is dimethyl sulfoxide.
    [291] Compounds of formula (II) in which R 21 , R 22 , R 24 , R 31 , R 33 and X are as defined above may be prepared from compounds of formula (III) using the method described in European patent application 0511845 or 0659745:
    [292]
    [293] Wherein R 21 , R 22 , R 31 , R 33 and X are as defined above.
    [294] According to a feature of the invention, R 21 , R 22 , R 31 , R 33 and X are as defined above and R 24 is -N = C (R 25 ) -NR 26 R 27, wherein R 25 R 26 and R 27 may be prepared by reacting a compound of Formula II with a compound of Formula IV as defined above:
    [295]
    [296] Wherein R 25 , R 26 and R 27 are as defined above and R 100 is generally an alkyl group. The reaction is generally carried out optionally in the presence of a catalyst such as mineral or organic acid (eg hydrochloric acid), preferably using 1 to 100 equivalents of IV, preferably 1 to 10 equivalents of IV, preferably In an organic solvent such as tetrahydrofuran, toluene, or N, N-dimethylformamide. Additional auxiliaries such as desiccants (eg magnesium sulphate, potassium carbonate, or molecular sieves) may also be advantageous for the reaction. Compounds of formula IV are known or can be prepared by known processes.
    [297] According to a feature of the invention, R 21 , R 22 , R 31 , R 33 and X are as defined above and R 24 is -N = C (R 25 ) -NR 26 R 27, wherein R 25 R 26 and R 27 may be prepared by reacting a compound of Formula II with a compound of Formula VI as defined above:
    [298]
    [299] Wherein R 21 , R 22 , R 25 , R 31 , R 33 , X and R 100 are as defined above;
    [300]
    [301] Wherein R 26 and R 27 are as defined above. The reaction is generally carried out using the same conditions used for the preparation of the compounds of the formula (II) by reaction of the compounds of the formula (IV) with the compounds of the formula (III).
    [302] According to a feature of the invention, R 24 is -N = C (R 25 ) -NR 27 R 28 and R 21 , R 22 , R 25 , R 27 , R 31 , R 33 and X are as defined above , R 28 is COR 34 , wherein R 34 is a compound of formula II as defined above, wherein the corresponding compound of formula II wherein R 24 is -N = C (R 25 ) NR 27 H and the acid chloride of formula It can be prepared by reaction with:
    [303]
    [304] Wherein R 34 is as defined above. The reaction is generally carried out in the presence of a base such as trialkylamine, for example triethylamine, in a solvent such as dichloromethane at a temperature of 0 ° C. to 50 ° C.
    [305] According to a feature of the invention, R 24 is -N = C (R 25 ) -NR 27 R 28 and R 21 , R 22 , R 25 , R 27 , R 31 , R 33 and X are as defined above Or a compound of formula II wherein R 28 is -S (O) tR 30 , wherein the corresponding compound of formula II wherein R 24 is -N = C (R 25 ) -NR 27 H and the sulfonyl chloride or It can be prepared by reaction with chloride:
    [306]
    [307] The reaction is generally carried out at 0 ° C. to 50 ° C. in a solvent such as dichloromethane in the presence of a weak base such as trialkylamine, for example triethylamine, or pyridine.
    [308] Compounds of formula (VI), (VII) and (VII) are known or may be prepared by known processes. Compounds III and V are generally known methods, for example international patent applications WO 87/3781, WO 93/6089, WO 94/21606, WO 97/07102, WO 98/24767, WO 98/28277, WO 98 / 28278 and WO 98/28279, European Patent Application 295117, 846686, and US Patent 5232940.
    [309] In another aspect of the invention, R 204 is -N (R 205 ) C (O) CR 206 R 207 R 208 , N (R 205 ) C (O) aryl, or N (R 205 ) C (O) OR Compounds of formula (XX), which are 207 , are generally halides of formula (X 2 C (O) CR 206 R 207 R 208 , X 2 C (O) aryl, or X 2 C (O) OR 207 Prepared by reaction with:
    [310]
    [311] [Wherein, R 201 , R 202 , R 205 , R 206 , R 207 , R 208 , R 211 , R 213 , and X 1 are as defined above, wherein X 2 is a halogen atom]. The reaction is generally carried out in the presence of a base, generally using 1 to 10 molar equivalents of halide, preferably at a temperature of 0 ° C. to 150 ° C., in the presence of an organic solvent such as tetrahydrofuran, methylene chloride. do.
    [312] Compounds of formula (XXI) may be prepared by reaction with compounds of formula (XXIII) from compounds of formula (XXII):
    [313]
    [314]
    [315] Wherein R 201 , R 202 , R 205 , R 211 , R 213 , and X 1 and X 2 are as defined above. Compounds of formula (XXIII) are generally known in the art, such as alkyl halides or substituted alkyl halides. Compounds of formula XXII are described in international patent applications WO 87/3781, WO 93/6089, WO 94/21606, WO 97/07102, WO 98/24767, WO 98/28277, WO 98/28278 and WO 98/28279, European patents Applications 295117, 659745, 846686, and US Pat. No. 5,232,940 or other methods known to those skilled in the art.
    [316] Alternatively, compounds of formula XXI can be prepared by reduction of compounds of formula XXIV:
    [317]
    [318] Wherein R 201 , R 202 , R 211 , R 213 and X 1 are as defined above. Reduction can generally be accomplished by the use of standard hydride ion donors such as sodium borohydride or sodium cyanoborohydride. The reaction is generally accomplished in polar solvents such as ethanol or methanol, using 1 to 10 molar equivalents of hydride, and is preferably carried out at temperatures of -100 ° C to 150 ° C.
    [319] Compounds of formula XXIV can be prepared using the methods described in EP 295117, WO 97/22593, or other methods known to those skilled in the art.
    [320] In another aspect of the invention, 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-ethoxymethylidene, an intermediate useful in the preparation of compounds for use according to the invention Amino-4-trifluoromethylsulfinylpyrazole and 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-methylamino-4-trifluoromethylsulfinylpyrazole To provide a compound.
    [321] Biological example
    [322] The following compounds are formulated as 30 mg / mL formulations in a 1: 1 volumetric dimethylsulfoxide and corn oil solution:
    [323]
    [324] Using this formulation, hybrid dogs and cats were treated at a rate of 10 mg (mg / kg) of compound per kg body weight of the dog and cats were treated at 20 mg / kg. Animals were fasted for at least 8 hours prior to treatment, fed half of the feed for one day immediately before treatment and then given the rest of the feed for one day immediately after treatment.
    [325] All dogs were infected with cat fleas (Ctenocephalides felis) and ticks (Rhipicephalus sanguineus) one day before compound administration. Cats were only infected with fleas. Initial flea and tick counts were performed one day after administration of the compound. Dogs were infected with ticks at 7, 14, 21 and 28 days after treatment and dogs and cats were reinfected with fleas at 8, 15, 22 and 29 days after treatment. In dogs and cats treated 1, 9, 16, 23 and 30 days post-treatment, fleas and ticks for infected dogs and cat groups given placebos consisting of dimethylsulfoxide and corn oil in a volume ratio of 1: 1. Inhibition of was determined. To determine the efficacy of the compound, arthropods were counted by combing from the animals.
    [326] In animals treated with the compound, there was substantially no vomiting for 2, 4 and 24 hours. In general, long term inhibition of fleas and ticks has been provided in dogs. In treated cats, there was a commercially acceptable inhibition of fleas for at least 1 day after treatment.
    [327] The results of this example are better than those obtained with compounds of the prior art, for example fipronil.
    [328] The following non-limiting synthesis examples illustrate the preparation of compounds of formula I and the reference examples illustrate the preparation of intermediates used in their synthesis.
    [329] Synthesis Example 1
    [330] 5-amino-3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -4-trifluoromethylthiopyrazole (1 g) in N, N-dimethylformamide dimethyl acetal Heated at 50 ° C. for 1 hour. Evaporation of the solvent gave 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-N'-dimethylaminomethylideneamino-4-trifluoromethylthiopyrazole ( Melting point 141 ° C.).
    [331] By proceeding in a similar manner, the following compounds were also prepared:
    [332] 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-N'-dimethylaminomethylideneamino-4-trifluoromethylsulfonylpyrazole (melting point 209 ° C.); And
    [333] 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-N'-dimethylaminomethylideneamino-4-trifluoromethylsulfinylpyrazole (melting point 207 ° C.)
    [334] Synthesis Example 2
    [335] A solution of 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-ethoxymethylideneamino-4-trifluoromethylthiopyrazole (5 g) in ethanol was benzylamine (11.4 ml), stirred overnight, evaporated and purified by reverse phase column chromatography (C-18 stationary column column, eluted with MeOH / water) to give 5-N'-benzylaminomethylideneamino-3-cyano. -1- (2,6-dichloro-4-trifluoromethylphenyl) -4-trifluoromethylthiopyrazole (1.18 g, melting point 113 DEG C) was obtained.
    [336] By proceeding in a similar manner, R 21 , shown in Table 4, is CN; R 24 is -N = CH-NHR 26 ; R 31 is Cl; X is C-Cl; Also prepared were compounds of formula II, wherein R 33 is CF 3 .
    [337] Table 4
    [338]
    [339] Reference Example 1
    [340] A solution of 5-amino-3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -4-trifluoromethylthiopyrazole (500 g) in triethyl orthoformate was concentrated Treated with hydrochloric acid (10 ml) and heated at 50 ° C. After 8 hours, the reaction mixture is evaporated to give a solid which is washed (heptane) and air dried to 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5- Toxymethylideneamino-4-trifluoromethylthiopyrazole (217 g, melting point 68 DEG C) was obtained.
    [341] By proceeding in a similar manner, the following intermediates were also prepared:
    [342] 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole (melting point 63 ° C.);
    [343] And 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-ethoxymethylideneamino-4-trifluoromethylsulfonylpyrazole (melting point 118 ° C.).
    [344] Synthesis Example 3
    [345] 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-methylamino-4-trifluoromethylsulfinylpyrazole (111.55 g, 0.247 mol), triethylamine (62.45 g, 0.618 mol), 4-dimethylaminopyridine (3 g, 0.0247 mol), and tetrahydrofuran (700 ml). The resulting solution was heated to 45 ° C. and ethoxyacetyl chloride (45.2 g, 0.37 mmol) was added dropwise over 10 minutes. After 1 h, the mixture was evaporated to give a brown residue which was dissolved in 500 ml of ethyl acetate and washed with 2 x 300 ml of water. The organic phase was dried over magnesium sulfate, filtered and evaporated to give a brown oil. The oil was triturated with 1 L hot cyclohexane. The resulting solids were collected by filtration, washed with 500 ml of hot cyclohexane and then air dried to afford compound 3-3 as a beige powder (116.7 g). The parent liquid was evaporated to afford the second crop, compound 3-3 (8.4 g).
    [346] The following compounds were prepared in a similar manner or by modifications according to methods known to those skilled in the art. Compound numbers in the left column refer to the tables cited above.
    [347]
    [348]
    [349]
    [350] Reference Example 2
    [351] Step A: Preparation of 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole.
    [352] A 12-L three-necked flask equipped with a water stirrer (eg Dean Stark trap) with an upper stirrer, heating mantle, condenser was placed under a nitrogen atmosphere and 1.475 kg (3.37 mol) of fipronil and 6 L of Filled with triethyl orthoformate. The suspension was heated to reflux over 2.5 hours and then the combined and distillate removed under reflux for 3 hours. The mixture was cooled to room temperature and then evaporated under a reduced pressure at a bath temperature of 60 to 80 ° C. and then at 50 ° C. The resulting beige solid, 1.717 kg (by 95.8% HPLC, 3.335 moles, 99% purity modified yield) was used without further purification (melting point about 63 ° C.).
    [353] Step B: Preparation of 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-methylamino-4-trifluoromethylsulfinylpyrazole.
    [354] 50 L reactor was run under nitrogen to 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-ethoxymethylideneamino-4-trifluoromethylsulfinylpyrazole (1.645 g, 3.335 moles) and absolute ethanol (16 L). The solution is cooled to 10 ° C and sodium borohydride (266 g, 7.03 mol) is added slowly to maintain the temperature generally below 35 ° C. After 6.75 hours, some additional sodium borohydride (25 g, 0.66 mol) is added and stirring is continued overnight. Acetic acid (1.3 L, 22.7 mol) is added and then quenched with 16 L of water. The resulting precipitate is collected by filtration, washed with water and air dried. Recrystallization from methanol gave 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5-methylamino-4-trifluoromethylsulfinylpyrazole (350 g) as off-white crystals. Obtained (melting point about 227 ° C.).
    权利要求:
    Claims (10)
    [1" claim-type="Currently amended] A method of inhibiting a parasite in an animal or in vitro, comprising orally administering to the animal a substantial non-vomiting amount of 1-arylpyrazole of Formula I and a veterinary acceptable salt thereof that has a parasitic effect:
    [Formula I]
    [Meal,
    R 1 is cyano, acetyl, C (S) NH 2 , alkyl, haloalkyl, C (═NOH) NH 2 or C (= NNH 2 ) NH 2 ;
    R 2 is S (O) nR 3 ; C 2 -C 3 alkenyl, C 2 -C 3 haloalkenyl, cycloalkyl, halocycloalkyl or C 2 -C 3 alkynyl;
    R 3 is alkyl or haloalkyl;
    R 4 is -N = C (R 5 ) -ZR 6 , -N = C (R 5 ) -N (R 7 ) -R 8 , or -N (R 9 ) -C (R 5 ) = NR 6 ;
    R 5 is hydrogen; Alkyl; Or halogen, alkoxy, haloalkoxy or alkyl substituted with -S (O) mR 15 ;
    R 6 and R 7 are each independently hydrogen, alkyl, C 3 -C 5 alkenyl or C 3 -C 5 alkynyl; or
    One or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or alkyl substituted with -S (O) mR 15 ; Or alkyl substituted with phenyl or pyridyl, each optionally substituted with one or more groups selected from halogen, nitro and alkyl; or
    R 6 and R 7 together with the nitrogen to which they are attached may form a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from oxygen, nitrogen or sulfur;
    R 8 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, R 14 CO- or —S (O) tR 10 ;
    R 9 , R 10 and R 14 are alkyl or haloalkyl;
    R 11 and R 12 are independently selected from halogen, hydrogen, CN and NO 2 ;
    R 13 is selected from halogen, haloalkyl, haloalkoxy, -S (O) qCF 3 , and -SF 5 ;
    R 15 is alkyl or haloalkyl;
    X is selected from nitrogen and CR 12 ;
    Z is O, S (O) a; Or NR 7 ;
    a, m, n and q are independently selected from 0, 1 and 2;
    t is 0 or 2].
    [2" claim-type="Currently amended] A method of inhibiting a parasite in or on an animal, comprising orally administering to the animal a substantially non-vomiting amount of 1-arylpyrazole of Formula (XX) and a veterinary acceptable salt thereof having a parasitic effect:
    [Formula XX]
    [In the meal,
    R 201 is cyano, C (O) alkyl, C (S) NH 2 , alkyl, C (═NOH) NH 2 or C (= NNH 2 ) NH 2 ;
    R 202 is S (O) hR 203 , C 2 -C 3 alkenyl, C 2 -C 3 haloalkenyl, cycloalkyl, halocycloalkyl or C 2 -C 3 alkynyl;
    R 203 is alkyl or haloalkyl;
    R 204 is —N (R 205 ) C (O) CR 206 R 207 R 208 , -N (R 205 ) C (O) aryl, or —N (R 205 ) C (O) OR 207 ;
    R 205 is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, cycloalkylalkyl, halocycloalkylalkyl, alkoxyalkyl, haloalkoxyalkyl, C 3 -C 5 alkenyl, C 3 -C 5 haloalkenyl, C 3 -C 5 alkynyl, C 3 -C 5 haloalkynyl;
    R 206 is hydrogen, halogen, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl, formyloxy, alkylcarbonyloxy, haloalkylcarbonyloxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, Alkylsulfonyl, haloalkylsulfonyl, alkylamino, dialkylamino, haloalkylamino, di (haloalkyl) amino, cycloalkyloxy, halocycloalkyloxy, alkoxyalkoxy, haloalkoxyalkoxy, alkoxyalkoxyalkoxy, aryloxy, Or arylalkoxy;
    R 207 and R 208 are independently hydrogen, alkyl, haloalkyl, cycloalkyl, or halocycloalkyl; Or R 207 and R 208 together with the carbon to which they are bound may form a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;
    X 1 is selected from nitrogen and CR 212 ;
    R 211 and R 212 are independently selected from halogen, hydrogen, CN and NO 2 ;
    R 213 is selected from halogen, haloalkyl, haloalkoxy, -S (O) kCF 3 , and -SF 5 ;
    h and k are independently selected from 0, 1 and 2].
    [3" claim-type="Currently amended] The method of claim 1, wherein the compound of formula I is
    R 1 is cyano or alkyl;
    R 2 is S (O) nR 3 ;
    R 3 is alkyl or haloalkyl;
    R 4 is -N = C (R 5 ) -ZR 6 ;
    R 5 is hydrogen, alkyl or haloalkyl;
    Z is O, S (O) a; Or NR 7 ;
    R 6 and R 7 are independently selected from hydrogen and unsubstituted or substituted alkyl; or
    R 6 and R 7 together with the nitrogen to which they are attached form a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from oxygen, nitrogen or sulfur; X is selected from nitrogen and CR 12 ;
    R 11 and R 12 are independently selected from halogen, hydrogen, CN and NO 2 ;
    R 13 is selected from halogen, haloalkyl, haloalkoxy, -S (O) qCF 3 , and -SF 5 ;
    a, n and q are independently selected from 0, 1 and 2.
    [4" claim-type="Currently amended] The method of claim 2, wherein the compound of Formula XX is as follows:
    R 201 is cyano;
    R 202 is S (O) hR 203 ;
    R 203 is alkyl or haloalkyl;
    R 204 is —N (R 205 ) C (O) CR 206 R 207 R 208 ;
    R 205 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl and halocycloalkylalkyl;
    R 206 is alkoxy, haloalkoxy, or hydrogen;
    R 207 and R 208 are independently hydrogen, alkyl, or haloalkyl; or
    R 207 and R 208 together with the carbon to which they are bound may form a 3 to 7 membered ring which may additionally contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;
    X 1 is selected from nitrogen and CR 212 ;
    R 211 and R 212 are independently selected from halogen, hydrogen, CN and NO 2 ;
    R 213 is selected from halogen, haloalkyl, haloalkoxy, -S (O) kCF 3 , and -SF 5 ;
    h and k are independently 0, 1, and 2.
    [5" claim-type="Currently amended] Compound of Formula (II) or veterinary acceptable salt thereof:
    [Formula II]
    [In the meal,
    R 21 is cyano, alkyl, haloalkyl, acetyl, or -C (= S) NH 2, C (= NOH) NH 2 or C (= NNH 2) NH 2, and;
    R 22 is S (O) mR 23 ;
    R 23 is alkyl or haloalkyl;
    R 24 is -N = C (R 25 ) N (R 26 ) (R 27 ) or -N = C (R 25 ) -N (R 27 ) -R 28 ;
    R 25 is hydrogen or alkyl; Or alkyl substituted with one or more halogen, alkoxy, haloalkoxy or -S (O) mR 35 ;
    R 26 and R 27 are each independently hydrogen, alkyl, alkenyl or alkynyl; Or alkyl substituted with one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or -S (O) mR 35 ; Or alkyl substituted with phenyl or pyridyl optionally substituted with one or more groups selected from halogen, nitro and alkyl; Wherein R 35 is alkyl or haloalkyl and m is 0, 1 or 2;
    X is selected from nitrogen and CR 32 ;
    R 28 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino or —S (O) tR 30 ;
    R 30 is alkyl or haloalkyl;
    R 31 and R 32 are independently selected from halogen, hydrogen, CN and NO 2 ;
    R 33 is selected from halogen, haloalkyl, haloalkoxy, -S (O) rCF 3 , and -SF 5 ;
    m and r are independently selected from 0, 1 and 2; t is 0 or 2;
    Provided that R 21 is cyano; R 22 is SCF 2 CH 3 ; R 25 is hydrogen; X is CR 32 ; R 26 and R 27 are methyl; R 31 and R 32 are chlorine; Compounds wherein R 33 is trifluoromethyl are excluded.
    [6" claim-type="Currently amended] The compound of claim 2 is 3-cyano-1- (2,6-dichloro-4-trifluoromethylphenyl) -5- (N-ethoxycarbonyl-N-methyl) amino-4-trifluoromethylthio Compounds of formula (XX) or salts thereof that are not pyrazoles.
    [7" claim-type="Currently amended] A composition comprising a substantially non-vomiting amount of a compound of formula (I) or a salt thereof, or a compound of formula (XX) or a salt thereof, and an acceptable carrier, having a parasitic effect.
    [8" claim-type="Currently amended] The method according to any one of claims 1 to 4, wherein the animal is a livestock, preferably a dog or a cat.
    [9" claim-type="Currently amended] 9. The method of claim 1, 2, 3, 4 or 8 wherein the 1-arylpyrazole is orally administered to the animal in a single dose of generally 0.1 to 500 mg / kg.
    [10" claim-type="Currently amended] The method of claim 1, 2, 3, 4, 8, or 9, wherein the 1-arylpyrazole is administered at a treatment frequency of about once per week to about once per year.
    类似技术:
    公开号 | 公开日 | 专利标题
    US9044389B2|2015-06-02|Isoxazoline derivatives as pesticides
    ES2542409T3|2015-08-05|Isoxazole derivatives
    AU2012215440B2|2015-08-27|Isoxazoline derivatives for controlling invertebrate pests
    CA1330089C|1994-06-07|Derivatives of n-phenylpyrazoles
    EP0385809B1|1995-07-05|Pesticidal 3-cyano-5-alkoxy-1-arylpyrazoles
    CA2275920C|2008-07-15|Pesticidal 1-arylpyrazoles
    JP5632290B2|2014-11-26|Aminobenzamide derivatives as useful agents for controlling animal parasites
    EP0500209B1|1997-09-17|Pesticidal 1-|pyrazoles
    CA2275635C|2008-11-25|Pesticidal 1-arylpyrazoles
    US5939441A|1999-08-17|Substituted pyridylpyrazoles
    CN103517907B|2016-07-06|Volution isoxazolines derivative as antiparasitic
    US5236938A|1993-08-17|Pesticidal 1-aryl-5-|pyrazoles
    JP3083278B2|2000-09-04|Parasiticidal compounds
    KR101667063B1|2016-10-17|Ortho-substituted haloalkylsulfonanilide derivative and herbicide
    US5506260A|1996-04-09|Pesticidal 1-arylpyrrole compositions and method of use thereas
    ES2442342T3|2014-02-11|Isoxazoline derivatives and their use as a pesticide
    AU606349B2|1991-02-07|Method of preventing the reinfestation of dogs and cats by fleas
    JP2870650B2|1999-03-17|N-phenylpyrazole derivative
    US5556873A|1996-09-17|Pesticidal 1-aryl-5-| amido)pyrazoles
    AP1004A|2001-08-28|Pesticidal 1-aryl and pyridylpyrazole derivatives.
    EP2582696B1|2014-10-22|5-aryl isoxazolines for controlling pests
    USRE37936E1|2002-12-10|Pesticidal 1-polyarylpyrazoles
    EP0403300B1|1995-04-12|N-Phenylpyrazole derivatives
    US6069157A|2000-05-30|Parasiticidal compounds
    EP0235628B1|1991-04-24|1-arylpyrazoles
    同族专利:
    公开号 | 公开日
    IL143140A|2008-08-07|
    JP4757385B2|2011-08-24|
    HRP20010437B1|2011-09-30|
    YU39201A|2004-07-15|
    EP1137639A1|2001-10-04|
    CA2355214C|2010-02-23|
    CN1329600A|2002-01-02|
    JP2002532477A|2002-10-02|
    MA25274A1|2001-10-01|
    HK1042900A1|2005-04-01|
    US6160002A|2000-12-12|
    SK287275B6|2010-05-07|
    CO5140086A1|2002-03-22|
    AU3044200A|2000-07-03|
    SK7902001A3|2003-02-04|
    IL184501A|2008-08-07|
    EP1137639B1|2009-08-19|
    AP200102163A0|2001-06-30|
    PL352400A1|2003-08-25|
    AT440086T|2009-09-15|
    KR20070020145A|2007-02-16|
    ID30036A|2001-11-01|
    OA11809A|2005-08-17|
    AP2001002163A0|2001-06-30|
    AU770796B2|2004-03-04|
    NZ511706A|2003-12-19|
    AR021608A1|2002-07-31|
    HRP20010437A2|2002-06-30|
    CZ20012030A3|2002-03-13|
    IL143140D0|2002-04-21|
    NO20012820L|2001-08-13|
    IL184500A|2008-08-07|
    WO2000035884A1|2000-06-22|
    CU23113A3|2006-02-27|
    NO320018B1|2005-10-10|
    EA004144B1|2004-02-26|
    CZ303314B6|2012-08-01|
    CN1154638C|2004-06-23|
    NO20012820D0|2001-06-07|
    BRPI9916967B1|2016-04-12|
    CA2355214A1|2000-06-22|
    EE05363B1|2010-12-15|
    KR100859295B1|2008-09-19|
    AP1603A|2006-04-28|
    BR9916967A|2001-09-25|
    HK1042900B|2005-04-01|
    KR100791407B1|2008-01-07|
    ES2331672T3|2010-01-12|
    EA200100653A1|2001-12-24|
    BG105603A|2002-01-31|
    HU0104636A3|2002-04-29|
    DE69941303D1|2009-10-01|
    EE200100307A|2002-12-16|
    BG65289B1|2007-12-28|
    HU0104636A2|2002-03-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    1998-12-11|Priority to US11185798P
    1999-06-24|Priority to US14068099P
    1999-06-24|Priority to US60/111,857
    1999-06-24|Priority to US60/140,680
    1999-12-10|Application filed by 추후제출, 아벤티스 크롭사이언스 소시에떼아노님
    2001-12-07|Publication of KR20010108006A
    2008-01-07|Application granted
    2008-01-07|Publication of KR100791407B1
    优先权:
    申请号 | 申请日 | 专利标题
    US11185798P| true| 1998-12-11|1998-12-11|
    US14068099P| true| 1999-06-24|1999-06-24|
    US60/111,857|1999-06-24|
    US60/140,680|1999-06-24|
    [返回顶部]